Pharmaxis Announces Placement of $47 Million and Share Purchase Plan
04 6월 2009 - 9:19AM
PR Newswire (US)
SYDNEY, June 3 /PRNewswire-Asia/ -- Pharmaxis
(ASX:PXSASX:Nasdaq:ASX:PXSL) today announced that it had raised
A$47 million through a placement to Australian and international
institutions and professional investors. The placement strengthens
the company's balance sheet as Pharmaxis moves toward the European
and U.S. commercial launch of its product Bronchitol for cystic
fibrosis. Pharmaxis will issue 20 million new fully paid ordinary
shares at A$2.35 per share, a 10.6% discount to Pharmaxis' last
closing price on 1 June 2009 and an 8.5% discount to the volume
weighted average share price over the past 30 days. The shares to
be issued will rank equally with existing ordinary shares in the
capital of the company. The placement has been managed by Wilson
HTM Corporate Finance Limited and closed oversubscribed. Settlement
of the placement is scheduled to take place on 10 June 2009. A
share purchase plan will be offered to all Australian and New
Zealand shareholders who hold shares as at 7.00pm on 1 June 2009
and will afford the opportunity to purchase up to $5,000 worth of
fully paid ordinary shares at the placement price of A$2.35,
without brokerage or transaction costs. The share purchase plan
offer opens on 10 June and closes on 24 June 2009. The share
purchase plan will be capped at A$10 million. "The proceeds from
this offering are principally to be used for the commercial launch
of Bronchitol for cystic fibrosis in both Europe and the U.S. This
placement means Pharmaxis can take an important additional step in
building a profitable, international, pharmaceutical business. We
are very pleased with the support from the participating
institutions and look forward to bringing Bronchitol to the world,"
said Pharmaxis Chief Executive Officer Dr Alan Robertson.
Forward-Looking Statements The statements contained in this media
release that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements in
this media release include statements regarding our expectations,
beliefs, hopes, goals, intentions, initiatives or strategies,
including statements regarding the potential for Aridol and/or
Bronchitol. All forward-looking statements included in this media
release are based upon information available to us as of the date
hereof, and we assume no obligation to update any such
forward-looking statement as a result of new information, future
events or otherwise. We can not guarantee that any product
candidate will receive FDA or other regulatory approval or that we
will seek any such approval. Factors that could cause or contribute
to such differences include, but are not limited to, factors
discussed in the "Risk Factors and Other Uncertainties" section of
our Form 20-F lodged with the U.S. Securities and Exchange
Commission. CONTACT: Alan Robertson - Chief Executive Officer Tel:
+61-2-9454-7200 Email: RELEASED THROUGH: Australia: Felicity
Moffatt Tel: +61-418-677-701 Email: United States: Brandon Lewis,
Trout Group Tel: +1-646-378-2915 Email: DATASOURCE: Pharmaxis Ltd
CONTACT: Alan Robertson, Chief Executive Officer of PXSL,
+61-2-9454- 7200, or
Copyright